Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole

Author:

Chapman Judith-Anne W.1,Bayani Jane23ORCID,SenGupta Sandip4,Bartlett John M.S.5,Piper Tammy5,Quintayo Mary Anne2,Virk Shakeel6ORCID,Goss Paul E.7,Ingle James N.7ORCID,Ellis Matthew J.8ORCID,Sledge George W.9ORCID,Budd G. Thomas10ORCID,Rabaglio Manuela11ORCID,Ansari Rafat H.12,Tozer Richard13,D'Souza David P.14,Chalchal Haji15,Spadafora Silvana16,Stearns Vered17ORCID,Perez Edith A.718ORCID,Gelmon Karen A.19ORCID,Whelan Timothy J.13ORCID,Elliott Catherine6,Shepherd Lois E.6ORCID,Chen Bingshu E.6ORCID,Taylor Karen J.5ORCID

Affiliation:

1. Canadian Cancer Trials Group Queen's University, Kitchener, Canada

2. Ontario Institute for Cancer Research, Toronto, Canada

3. University of Toronto, Toronto, Canada

4. Queen's University, Kingston, Canada

5. University of Edinburgh, Edinburgh, United Kingdom

6. Canadian Cancer Trials Group Queen's University, Kingston, Canada

7. Harvard University, Boston, MA

8. Progendis, Gaithersburg, MD

9. Caris Life Sciences, Irving, TX

10. Cleveland Clinic, Cleveland, OH

11. Inselspital Bern, Bern, Switzerland

12. Indiana School of Medicine, South Bend, IN

13. McMaster University, Hamilton, Canada

14. London Regional Health Science Centre, London, Canada

15. Alan Blair Cancer Center, Regina, Canada

16. Algoma Regional Cancer Centre, Sault Ste Marie, Canada

17. Weill Cornell Medicine, New York, NY

18. Mayo Clinic, Redwood City, CA

19. University of British Columbia, Vancouver, Canada

Abstract

PURPOSE ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes. METHODS MA.27 (ClinicalTrials.gov identifier: NCT00066573 ) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (≤–1; (–1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance P < .05. RESULTS Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis results: 2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS ( P < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated ( P = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS ( P = .001) in models with ER. CONCLUSION Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ ≤–1.

Publisher

American Society of Clinical Oncology (ASCO)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3